Instil Bio Inc TIL

Healthcare Biotechnology

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

NDAQ:TIL - Post by User

Instil Bio Inc

Bullboard Posts

Comment by pennystockmoveron Jan 07, 2011 5:38pm

312 Views

Post# 17941502

RE: MPH. The next AMB!?

Had taken a postion here in November and December 2010. Sold most this week and kept some in hopes for news. Look at all you want in the Venture, but make sure you have a look at and do your dd on V.XRM ... Recent news puts it in a position to move upwards, and quickly.

GLTA

psm

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading